Newsroom

May 2016

• 
  Story May 20, 2016 From Our Labs

  With a "brain in a dish," researchers take on neurological disorders

  Neurological diseases develop out of sight. Novartis neuroscientists are bringing them into the light, using human brain cells grown in the lab.

• Press release May 19, 2016

  Novartis announces investment in FortiHFy clinical program of Entresto® and heart failure

  Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials   The global clinical program…
• Press release May 18, 2016

  Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting

  First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna® both in front-line and second-line following Glivec®*  First genomic analysis and 3-year…
• Press release May 18, 2016

  MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer

  Independent Data Monitoring Committee recommends stopping the trial early as it met the primary endpoint, significantly extending progression-free survival (PFS) compared to letrozole alone, at pre-…
• Press release May 17, 2016

  Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis

  Paul Hudson appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini appointed CEO, Novartis Oncology; David Epstein to leave Novartis  Paul Hudson and Bruno Strigini appointed to the…
• Press release May 17, 2016

  Novartis renforce la division Pharmaceuticals par la création de deux unités d'affaires, Novartis Pharmaceuticals et Novartis Oncology, et nomme de nouveaux dirigeants à son Comité de direction

  Paul Hudson devient CEO de Novartis Pharmaceuticals et Bruno Strigini devient CEO de Novartis Oncology ; David Epstein quitte Novartis   Paul Hudson et Bruno Strigini sont nommés au Comité…
• Press release May 17, 2016

  Novartis fokussiert ihre Division Pharmaceuticals durch Schaffung der Geschäftseinheiten Novartis Pharmaceuticals und Novartis Oncology und beruft deren Leiter in die Geschäftsleitung von Novartis

  Paul Hudson wird zum CEO, Novartis Pharmaceuticals, und Bruno Strigini zum CEO, Novartis Oncology, ernannt; David Epstein wird Novartis verlassen   Paul Hudson und Bruno Strigini werden in…
• Featured News May 17, 2016

  Fighting high blood pressure in Vietnam

  The Novartis Foundation is launching a blood pressure management program in Vietnam as part of its larger effort to combat the rise of chronic diseases in urban areas of developing countries.

• Press release May 17, 2016

  Novartis Foundation and partners launch innovative hypertension program in Vietnam

  Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation Screening and treatment shifts to the…
• 
  Story May 16, 2016 From Our Labs

  Electrical brainstorms traced to genetic mutations

  Researchers from Seattle Children’s and Novartis shed light on developmental brain disorders that lead to intractable epilepsy.

• Press release May 15, 2016

  Major study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbations

  FLAME study showed consistent superiority of Ultibro® Breezhaler® over Seretide® across exacerbation outcomes, lung function and health-related quality of life in COPD patients   Ultibro…
• 
  Story May 09, 2016 From Our Labs

  Eye disease tracked to a glitch in starburst cells

  A cellular computing error wreaks havoc on vision.